Avenir Wellness Solutions, Inc. (AVRW)
0.0002
0.00 (0.00%)
USD |
OTCM |
Aug 31, 16:00
Avenir Wellness Solutions Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 71.88% |
| June 30, 2024 | 62.02% |
| March 31, 2024 | 67.50% |
| December 31, 2023 | 57.93% |
| September 30, 2023 | 67.66% |
| June 30, 2023 | 66.67% |
| March 31, 2023 | 75.85% |
| December 31, 2022 | 10.19% |
| September 30, 2022 | 80.04% |
| June 30, 2022 | 67.50% |
| March 31, 2022 | 12.27% |
| December 31, 2021 | 33.60% |
| September 30, 2021 | 21.70% |
| June 30, 2021 | 30.46% |
| March 31, 2021 | 28.72% |
| December 31, 2020 | 44.27% |
| September 30, 2020 | 24.48% |
| June 30, 2020 | 62.83% |
| Date | Value |
|---|---|
| March 31, 2020 | 34.29% |
| December 31, 2019 | 5.60% |
| September 30, 2019 | -51.96% |
| June 30, 2019 | -110.9% |
| March 31, 2019 | 42.28% |
| December 31, 2018 | 53.50% |
| September 30, 2018 | 52.22% |
| June 30, 2018 | 55.39% |
| March 31, 2018 | 43.71% |
| December 31, 2017 | -30.68% |
| September 30, 2017 | 20.03% |
| June 30, 2017 | -63.75% |
| March 31, 2017 | -86.83% |
| December 31, 2016 | -223.5% |
| June 30, 2016 | -177.9% |
| March 31, 2016 | -59.79% |
| December 31, 2015 | |
| September 30, 2015 | 88.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Bespoke Extracts, Inc. | -- |
| Lyra Therapeutics, Inc. | -1.33K% |
| Bright Green Corp. | -- |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |